Fig. 3: Cross-neutralization of Rift Valley fever virus strains by sheep or cattle sera vaccinated with MP-12 or arMP12-∆NSm21/384. | npj Vaccines

Fig. 3: Cross-neutralization of Rift Valley fever virus strains by sheep or cattle sera vaccinated with MP-12 or arMP12-∆NSm21/384.

From: Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates

Fig. 3

A comparison was conducted on the amino acid sequences of Gn (a) or Gc (b) proteins among various strains of RVFV, including MP-12, ZH501, Kenya 9800523, Saudi Arabia 200010911, Zinga, OS1, SA75, Entebbe, and SA51. c The amino acid positions were determined based on the precursor protein from the first AUG start codon in the M-segment. In addition, the locations of neutralizing epitopes I, II, and IV181 were indicated. TMD refers to the transmembrane domain, while CT stands for cytoplasmic tail. In another experiment, sera obtained from pregnant ewes or cattle vaccinated with either MP-12 or rMP12-ΔNSm21/38498,99 were serially four-fold diluted. These diluted sera were then incubated with approximately 50 PFU of MP-12, wild-type Kenya 199800523, rZinga, wild-type OS1, wild-type Entebbe, or wild-type SA51 for the Plaque Reduction Neutralizing Test (PRNT). The percentage reduction in plaque numbers was calculated by comparing the plaque number with a normal control serum, which was set as 100%. This figure has been adopted from Ikegami et al.58.

Back to article page